Table 1.
Composition of different hybrid nanoparticles.
Table 2.
The toxicity and p53 knockdown efficiency of different hybrid nanoparticles.
Fig 1.
Determination of siRNA’s encapsulation efficiency of different hybrid nanoparticles.
The encapsulated siRNA in different formulations (T1-T8) was decomplexed by exposure to 1% SDS for 18 h and then measured by Ribogreen Assay. The results represent mean ± standard deviation (n = 4).
Table 3.
Comparison of particle size between blank nanoparticles and siRNA-loaded nanoparticles.
Fig 2.
Cryo-TEM pictures of different blank hybrid nanoparticles.
Scale bar represents 100 nm.
Table 4.
Comparison of zeta potential between blank nanoparticles and siRNA-loaded nanoparticles.
Fig 3.
Identification of the formulation with the best knockdown efficiency by western blotting following nanoparticle transfection with different formulation (A. T1 and T2; B. T3-T8).
318–1 cells were transfected with different formulations encapsulating either three different concentrations of p53 siRNA (i.e. 100, 125 and 150 pmol) (Fig 3A) or 150 pmol siRNA (Fig 3B). Representative western blotting results for p53, actin and vinculin are shown. This experiment was performed 3 independent times.
Fig 4.
Determination of the optimal siRNA concentration to knockdown mutant p53.
318–1 cells were transfected with different concentrations of control or p53 siRNA encapsulated in T4 hybrid nanoparticles followed by western blotting for p53 and vinculin (Fig 4A). Graph represents summary of knockdown efficiency from 3 independent experiments (Fig 4B).
Table 5.
Knockdown efficiency of hybrid nanoparticle at different transfection media volume.
Table 6.
Knockdown efficiency of T4 stored at different temperature up to 7 days.
Table 7.
Mutant p53 knockdown efficiency of T4 using different amount of cells.